Business of the House Debate

Full Debate: Read Full Debate
Department: Leader of the House

Business of the House

Matthew Offord Excerpts
Thursday 6th March 2014

(10 years, 8 months ago)

Commons Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Lord Lansley Portrait Mr Lansley
- Hansard - - - Excerpts

The Government have no blind spot in relation to Liverpool. On the contrary, many of the things we are doing are helping Liverpool. Speaking personally, when I was Secretary of State for Health, two of the most important future building projects to which I gave my personal support were the rebuilding of Liverpool Broadgreen and Alder Hey hospitals. That does not ignore Liverpool; it supports Liverpool in the continuation of one of its most important services. I will not reiterate the points the Prime Minister made yesterday. He set out very clearly the figures for the level of support received per household in Liverpool relative to other places.

Matthew Offord Portrait Dr Matthew Offord (Hendon) (Con)
- Hansard - -

Between 1997 and 2011, the number of prescriptions for methylphenidate hydrochloride—also known as Ritalin—rose from 92,079 to 929,839, which is a 1,000% increase. As the drug is commonly used to treat children with attention deficit hyperactivity disorder, may we have an urgent debate about the effects on society of drugging a generation of children?

Lord Lansley Portrait Mr Lansley
- Hansard - - - Excerpts

I know that there have been such debates, if not in the most recent past. If my hon. Friend and other Members feel strongly about these issues, they might together choose to ask the Backbench Business Committee to find time to explore them—if not in the Chamber, then in Westminster Hall.

As my hon. Friend knows, a range of factors affects the number of prescriptions. During as long a period as 1997 to 2010, much of course happened in relation to awareness about such conditions and the overall level of prescribing and treatment for ADHD generally. The National Institute for Health and Clinical Excellence guidance in 2006 and the clinical guidelines in 2008 have had an impact on prescribing by clinicians. I say all that merely to illustrate that there is a range of issues, but he is right to say that it is sometimes useful for this House to take the time to look at them.